For 454 Technology, Roche Bets on Specific Apps, Taking Share from Sanger | GenomeWeb

By Julia Karow

This story was originally published on August 5.

Roche plans to take "significant share" from the Sanger sequencing market as well as focus on specific applications, including medical ones, for its 454 technology, according to 454 Life Sciences' CEO.

In addition, with its partner IBM, the company is developing a successor technology that it estimates will take five to seven years to bring to market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.